A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)
Patients with stage III non-small cell lung cancer (NSCLC) and poor performance status (PS) and/or weight loss (WL) do not seem to benefit from standard therapy. Based on the pre-clinical interaction between epidermal growth factor receptor (EGFR) inhibitors and radiation, we designed a trial of induction chemotherapy followed by thoracic radiotherapy (TRT) and concurrent erlotinib.
Pharmacology, Toxicology and Pharmaceutical Science
1
2%
Other
5
12%
Unknown
14
34%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 January 2015.
All research outputs
#15,517,312
of 25,373,627 outputs
Outputs from Journal of Thoracic Oncology
#1,939
of 3,511 outputs
Outputs of similar age
#190,899
of 359,515 outputs
Outputs of similar age from Journal of Thoracic Oncology
#27
of 69 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,511 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,515 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
